Endogena Therapeutics
Latest round
- Series A
Last raised
- Dec 2021
Total raised
- $15M
Investors
- 2
About Endogena Therapeutics
Founded in 2016 in San Francisco, US, Endogena Therapeutics, Inc. specializes in regenerative medicine solutions.48 mn.Endogena Therapeutics specializes in the discovery and development of endogenous regenerative medicines aimed at treating degenerative diseases, particularly those affecting vision and lung function. The company’s primary offerings include innovative small molecule therapies designed to selectively regulate adult stem and progenitor cells for tissue repair. Their lead product, EA-2353, targets retinitis pigmentosa, a genetic disorder that leads to progressive vision loss, and is currently in Phase 1/2a clinical trials. The company aims to address significant unmet medical needs in markets across North America and Europe, specifically targeting healthcare providers and institutions involved in ophthalmology and pulmonary care.Endogena Therapeutics generates revenue primarily through partnerships with healthcare institutions and by progressing its clinical trial programs for novel therapies. The company may engage in collaborative agreements with pharmaceutical firms and research organizations, facilitating the development and commercialization of its products. While specific pricing structures for their therapies are not disclosed, typical transactions may involve milestone payments tied to clinical trial advancements, as well as potential royalties on future sales of approved products. The company's flagship therapy, EA-2353, is expected to attract interest from healthcare providers seeking innovative treatments for patients with retinitis pigmentosa, contributing to their revenue model. The company is targeting expansion into North America and Europe, with a focus on ophthalmology and pulmonary care markets.
Who invested in Endogena Therapeutics
2 investors across 2 rounds
See all investors in Endogena Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Endogena Therapeutics
Who invested in Endogena Therapeutics?
Endogena Therapeutics has 2 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Endogena Therapeutics raised?
Endogena Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Endogena Therapeutics last raise money?
Endogena Therapeutics's most recent round on record is a Series A, in Dec 2021.
What does Endogena Therapeutics do?
Founded in 2016 in San Francisco, US, Endogena Therapeutics, Inc.
Where is Endogena Therapeutics headquartered?
Endogena Therapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like Endogena Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Endogena Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Endogena Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.